Ken Griffin Viking Therapeutics, Inc. Put Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$49.84 - $70.47 $31.9 Million - $45.1 Million	640,100 Added 98.02%	1,293,100 $81.9 Million
Q2 2024 Aug 14, 2024	SELL	$47.39 - $80.2 $12.5 Million - $21.2 Million	-264,500 Reduced 28.83%	653,000 $34.6 Million
Q1 2024 May 15, 2024	BUY	$17.4 - $94.5 $11.9 Million - $64.7 Million	684,400 Added 293.61%	917,500 $75.2 Million
Q4 2023 Feb 14, 2024	BUY	$9.24 - $19.64 $291,060 - $618,660	31,500 Added 15.63%	233,100 $4.34 Million
Q3 2023 Nov 14, 2023	SELL	$10.92 - $16.0 $1.6 Million - $2.34 Million	-146,500 Reduced 42.09%	201,600 $2.23 Million
Q2 2023 Aug 14, 2023	BUY	$14.84 - $24.79 $673,736 - $1.13 Million	45,400 Added 15.0%	348,100 $5.64 Million
Q1 2023 May 15, 2023	BUY	$8.08 - $17.33 $1.17 Million - $2.5 Million	144,500 Added 91.34%	302,700 $5.04 Million
Q4 2022 Feb 14, 2023	BUY	$2.72 - $9.4 $307,632 - $1.06 Million	113,100 Added 250.78%	158,200 $1.49 Million
Q3 2022 Nov 14, 2022	BUY	$2.55 - $3.89 $254 - $389	100 Added 0.22%	45,100 $123,000

474

66.2M

5.72M

3.39M

Ticker VKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,688,496
Market Cap $3.62B
Description
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.